Reunion Neuroscience will be advancing its psychedelic therapy RE104 to a Phase III trial in post-partum depression (PPD) in ...

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

THL Partners has announced its agreement to purchase Headlands Research, a clinical trial sites network, from KKR-managed ...

MASLD is among the most common types of chronic liver disease and is estimated to affect 30% of the global population.

As antimicrobial resistance (AMR) escalates and chronic viral infections like human immunodeficiency virus (HIV) and herpes ...

Natera’s Signatera assay has been shown to improve outcomes in molecular residual disease (MRD)-positive patients with muscle-invasive bladder cancer (MIBC) when used as a companion diagnostic in a ...

The therapy is under development initially for treating obesity. Credit: nito / Shutterstock.com. BioAge Labs has dosed the first subject in the randomised Phase I study of BGE-102, an orally ...